EFFECTIVE LONG TERM PROPHYLAXIS OF HBV REACTIVATION AFTER LIVER TRANSPLANTATION WITH LAMIVUDINE AND LOW DOSE HEPATITIS B IMMUNOGLOBULIN (HBIG).

2006 ◽  
Vol 82 (Suppl 2) ◽  
pp. 448
Author(s):  
&NA;
2019 ◽  
Vol 21 (6) ◽  
Author(s):  
Wei‐Chen Lee ◽  
Hong‐Shiue Chou ◽  
Tsung‐Han Wu ◽  
Chih‐Hsien Cheng ◽  
Chen‐Fang Lee ◽  
...  

2014 ◽  
Vol 28 (1) ◽  
pp. 41-44 ◽  
Author(s):  
Tomohiro Tanaka ◽  
Eberhard L Renner ◽  
Nazia Selzner ◽  
George Therapondos ◽  
Leslie B Lilly

BACKGROUND: Hepatitis B immunoglobulin (HBIG) given in combination with a nucleos(t)ide analogue has reduced the rate of recurrent hepatitis B virus (HBV) infection following liver transplantation (LT); however, the most effective protocol remains unclear.OBJECTIVE: To evaluate the use of tenofovir disoproxil fumarate (TDF) in combination with one year of low-dose HBIG.METHODS: Twenty-four adults who underwent LT for HBV-related liver disease at the University Health Network (Toronto, Ontario) and received TDF (± lamivudine) and one year of HBIG to prevent recurrent HBV infection from June 2005 to June 2011 were evaluated.RESULTS: The median length of follow-up post-LT was 29.1 months. Three patients died during the follow-up period. Patient survival was 100% and 84.1% at one and five years, respectively. None of the patients developed recurrent HBV infection. No significant adverse event was observed due to TDF administration; renal function pre- and post-LT were also acceptably preserved.CONCLUSION: The present study demonstrated that a short, finite course of low-dose HBIG combined with maintenance of long-term TDF staring before LT is cost-effective and safe. However, further prospective study involving a larger patient cohort with a longer followup period is required to confirm the results.


1998 ◽  
Vol 65 (12) ◽  
pp. S49 ◽  
Author(s):  
V A Luketic ◽  
M L Shiffman ◽  
A J Sanyal ◽  
R K Sterling ◽  
R A Fisher ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document